Etazolate
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Etazolate is a pyrazolopyridine derivative drug,[1] which acts as an anxiolytic.[2]
It has several mechanisms of action, acting as an adenosine antagonist,[3] a subtype-selective GABAA receptor partial agonist,[4] and a phosphodiesterase inhibitor selective for the PDE4 subtype.[5]
See also
References
- ↑ Ticku MK, Davis WC (1982). “Molecular interactions of etazolate with benzodiazepine and picrotoxinin binding sites”. J. Neurochem. 38 (4): 1180–2. PMID 6278085.
- ↑ Williams M. Anxioselective anxiolytics. Journal of Medicinal Chemistry. 1983 May;26(5):619-28. PMID 6132997
- ↑ Williams M, Jarvis MF. Adenosine antagonists as potential therapeutic agents. Pharmacology Biochemistry and Behaviour. 1988 Feb;29(2):433-41. PMID 3283781
- ↑ Zezula J, Slany A, Sieghart W. Interaction of allosteric ligands with GABAA receptors containing one, two, or three different subunits. European Journal of Pharmacology. 1996 Apr 22;301(1-3):207-14. PMID 8773466
- ↑ Wang P, Myers JG, Wu P, Cheewatrakoolpong B, Egan RW, Billah MM. Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. Biochemical and Biophysical Research Communications. 1997 May 19;234(2):320-4. PMID 9177268
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH